title: Effect of atosiban on rabbit embryo development and human sperm motility.
abstract: OBJECTIVE
  To investigate embryotoxic potential and effects on human sperm motility of the mixed vasopressin V(1a)/oxytocin receptor antagonist atosiban considered for novel indication of improvement of uterine receptivity in embryo-transfer recipients.
  
  
  METHODS
  One-cell rabbit embryo bioassay and human sperm motility bioassay were performed in control media or in media containing atosiban.
  
  
  METHODS
  Private center of reproductive medicine and academic research institute of reproduction biotechnology.
  
  
  METHODS
  Rabbit females (New Zealand and California, N = 15) aged 4.5-6.5 months.
  
  
  METHODS
  In vitro exposure of one-cell rabbit embryos and human sperm to atosiban in the range of therapeutic concentrations clinically occurring in human beings.
  
  
  METHODS
  Embryo development and sperm motility.
  
  
  RESULTS
  Preimplantation development of one-cell rabbit embryos was not affected by atosiban in the concentrations < or =15,000 nM, which was 50-fold higher than the mean plasma concentration reached during regular therapy (300 nM). Atosiban did not affect human sperm motility in concentrations of < or =3,000 nM, in other words, 10 times the human mean plasma concentration.
  
  
  CONCLUSIONS
  Clinical application of atosiban in the proposed indication may be safe for embryos because it is compatible with preimplantation rabbit embryo development and human sperm motility.
authors.affiliation: Center for Reproductive Medicine KRIOBANK, Bialystok, Poland. piotr.pierzynski@wp.pl <piotr.pierzynski@wp.pl>
authors.forename: Piotr
authors.initials: P
authors.lastname: Pierzynski
authors.forename: Barbara
authors.initials: B
authors.lastname: Gajda
authors.forename: Zdzislaw
authors.initials: Z
authors.lastname: Smorag
authors.forename: Allan Dahl
authors.initials: AD
authors.lastname: Rasmussen
authors.forename: Waldemar
authors.initials: W
authors.lastname: Kuczynski
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D047108:Embryonic Development / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011817:Rabbits; D013081:Sperm Motility / Q000187:drug effects* / Q000502:physiology; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D006727:Hormone Antagonists; C047046:atosiban; D014668:Vasotocin